鞘氨醇-1-磷酸受体调节疗法在多发性硬化治疗中的研究进展  

Advances in Sphingosine-1-phosphate Receptor Modulation Therapy in the Treatment of Multiple Sclerosis

作　　者：归甜甜 朱峰[2] 薛群[2] GUI Tian-tian;ZHU Feng;XUE Qun(Department of Neurology,the People’s Hospital of Guangxi Zhuang Autonomous Region,Nanning 530021,China;Department of Neurology,the First Affiliated Hospital of Soochow University,Suzhou 215006,China)

机构地区：[1]广西壮族自治区人民医院神经内科,南宁530021 [2]苏州大学附属第一医院神经内科,苏州215006

出　　处：《中国临床神经科学》2024年第1期111-120,共10页Chinese Journal of Clinical Neurosciences

摘　　要：多发性硬化是一种以中枢神经系统慢性炎症、脱髓鞘和轴突损伤为主要特征的自身免疫性疾病,发病机制至今仍未阐明。近10年来口服免疫调节治疗正在兴起,其中鞘氨醇-1-磷酸受体调节剂在多发性硬化的治疗中取得了令人瞩目的疗效。文中主要关注S1P/S1PR信号通路在治疗多发性硬化中的作用、机制和临床应用现状以及展望。Multiple sclerosis(MS)is an autoimmune disease that is characterized by central nervous system inflammation,demyelination,axonal loss.The pathogenesis of MS has not yet been elucidated.During the past decade,oral immunomodulating therapies is popular.Sphingosine-1-phosphate receptor(S1PR)modulator therapy for MS has impressive efficacy.This review is focus on the mechanism of action of S1P/S1PR in MS,current status and future prospects.

关 键 词：多发性硬化 鞘氨醇-1-磷酸受体调节疗法 芬戈莫德 西尼莫德 

分 类 号：R744.51[医药卫生—神经病学与精神病学]